The regulation of steroid action by sulfation and desulfation

Endocrine Reviews

Volumn 36, Issue 5, 2015, Pages 526-563

  Mueller, Jonathan W ^a   Gilligan, Lorna C ^a   Idkowiak, Jan ^a   Arlt, Wiebke ^a   Foster, Paul A ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; ESTRONE; ESTRONE SULFATE; MULTIDRUG RESISTANCE PROTEIN; ORGANIC ANION TRANSPORTER; POLYPEPTIDE; PRASTERONE; PRASTERONE SULFATE; PREGNENOLONE; STEROID; STERYL SULFATASE; SULFOTRANSFERASE; MULTIENZYME COMPLEX; PAPS SYNTHETASE; STEROID SULFOTRANSFERASE; SULFATE ADENYLYLTRANSFERASE;

ATTENTION DEFICIT DISORDER; AUTISM; CELLULAR DISTRIBUTION; GENE MUTATION; GENETIC VARIABILITY; HORMONAL REGULATION; HUMAN; HYDROLYSIS; HYPERANDROGENISM; METABOLIC DISORDER; MULTIPLE SULFATASE DEFICIENCY; NEOPLASM; NONHUMAN; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; STEROID DESULFATION; STEROID SULFATION; STEROIDOGENESIS; SULFATION; TARGET CELL; TISSUE DISTRIBUTION; X LINKED ICHTHYOSIS; ACTIVE TRANSPORT; ANIMAL; METABOLISM; MOLECULARLY TARGETED THERAPY; MUTATION;

ANIMALS; BIOLOGICAL TRANSPORT, ACTIVE; HUMANS; MOLECULAR TARGETED THERAPY; MULTIENZYME COMPLEXES; MUTATION; NEOPLASMS; STEROIDS; STERYL-SULFATASE; SULFATE ADENYLYLTRANSFERASE; SULFOTRANSFERASES;

EID: 84944457566     PISSN: None     EISSN: 0163769X     Source Type: Journal    
DOI: 10.1210/er.2015-1036     Document Type: Review

References (430)

1. KlyneW, Schachter B, Martin GF. The steroids of pregnant mares' urine; a method for the extraction of steroid sulphates and the isolation of allopregn-16-en-3β-ol-20-one sulphate. Biochem J. 1948;43:231-234.
2. Lipmann F. Biological sulfate activation and transfer. Science. 1958;128:575-580.
3. Klyne W. The C/D ring union in oestrone and equilenin. Nature. 1948;161:434.
4. Lewbart ML, Schneider JJ. Enzymatic synthesis of steroid sulfates. J Biol Chem. 1956;222:787-794.
5. Taylor AE, Keevil B, Huhtaniemi IT. Mass spectrometry and immunoassay:how to measure steroid hormones today and tomorrow. Eur J Endocrinol. 2015;173:D1-D12.
6. Schiøler V, Thode J. Six direct radioimmunoassays of estradiol evaluated. Clin Chem. 1988;34:949-952.
7. Stanczyk FZ, Jurow J, Hsing AW. Limitations of direct immunoassays for measuring circulating estradiol levels in postmenopausal women and men in epidemiologic studies. Cancer Epidemiol Biomarkers Prev. 2010;19:903-906.
8. Handelsman DJ, Wartofsky L. Requirement for mass spectrometry sex steroid assays in the Journal of Clinical Endocrinology and Metabolism. J Clin Endocrinol Metab. 2013;98:3971-3973.
9. Shackleton CH, Kletke C, Wudy S, Pratt JH. Dehydroepiandrosterone sulfate quantification in serum using highperformance liquid chromatography/mass spectrometry and a deuterated internal standard:a technique suitable for routine use or as a reference method. Steroids. 1990;55:472-478.
10. Wierman ME, Auchus RJ, Haisenleder DJ, et al. Editorial:The new instructions to authors for the reporting of steroid hormone measurements. Endocr Rev. 2014;35:849.
11. Badoud F, Grata E, Boccard J, et al. Quantification of glucuronidated and sulfated steroids in human urine by ultra-high pressure liquid chromatography quadrupole time-of-flight mass spectrometry. Anal Bioanal Chem. 2011;400:503-516.
12. Hosogi J, Tanaka H, Fujita K, et al. LC-MS/MS coupled with immunoaffinity extraction for determination of estrone, 17β-estradiol and estrone 3-sulfate in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2010;878:222-227.
13. Penning TM, Lee SH, Jin Y, Gutierrez A, Blair IA. Liquid chromatography-mass spectrometry (LC-MS) of steroid hormone metabolites and its applications. J Steroid Biochem Mol Biol. 2010;121:546-555.
14. Diez-Roux G, Ballabio A. Sulfatases and human disease. Annu Rev Genomics Hum Genet. 2005;6:355-379.
15. Hobkirk R. Steroid sulfation Current concepts. Trends Endocrinol Metab. 1993;4:69-74.
16. Ghosh D. Human sulfatases:a structural perspective to catalysis. Cell Mol Life Sci. 2007;64:2013-2022.
17. Suzuki T, Miki Y, Nakamura Y, Ito K, Sasano H. Steroid sulfatase and estrogen sulfotransferase in human carcinomas. Mol Cell Endocrinol. 2011;340:148-153.
18. Yen PH, Marsh B, Allen E, et al. The human X-linked steroid sulfatase gene and a Y-encoded pseudogene:evidence for an inversion of the Y chromosome during primate evolution. Cell. 1988;55:1123-1135.
19. Nardi A, Pomari E, Zambon D, Belvedere P, Colombo L, Dalla Valle L. Transcriptional control of human steroid sulfatase. J Steroid Biochem Mol Biol. 2009;115:68-74.
20. Shapiro LJ, Mohandas T, Weiss R, Romeo G. Non-inactivation of an x-chromosome locus in man. Science. 1979; 204:1224-1226.
21. Hernandez-Guzman FG, Higashiyama T, Pangborn W, Osawa Y, Ghosh D. Structure of human estrone sulfatase suggests functional roles of membrane association. J Biol Chem. 2003;278:22989-22997.
22. Nussbaumer P, Billich A. Steroid sulfatase inhibitors. Med Res Rev. 2004;24:529-576.
23. Thomas MP, Potter BV. The structural biology of oestrogen metabolism. J Steroid Biochem Mol Biol. 2013;137:27-49.
24. Conary J, Nauerth A, Burns G, Hasilik A, von Figura K. Steroid sulfatase. Biosynthesis and processing in normal and mutant fibroblasts. Eur J Biochem. 1986;158:71-76.
25. von Figura K, Schmidt B, Selmer T, Dierks T. A novel protein modification generating an aldehyde group in sulfatases:its role in catalysis and disease. Bioessays. 1998; 20:505-510.
26. Stein C, Hille A, Seidel J, et al. Cloning and expression of human steroid-sulfatase. Membrane topology, glycosylation, and subcellular distribution in BHK-21 cells. J Biol Chem. 1989;264:13865-13872.
27. Stengel C, Newman SP, Day JM, Tutill HJ, Reed MJ, Purohit A. Effects of mutations and glycosylations on STS activity:a site-directed mutagenesis study. Mol Cell Endocrinol. 2008;283:76-82.
28. Schmidt B, Selmer T, Ingendoh A, von Figura K. A novel amino acid modification in sulfatases that is defective in multiple sulfatase deficiency. Cell. 1995;82:271-278.
29. Wirth B, Herrmann FH, Neugebauer M, et al. Linkage analysis in X-linked ichthyosis (steroid sulfatase deficiency). Hum Genet. 1988;80:191-192.
30. Shapiro LJ, Yen P, Pomerantz D, Martin E, Rolewic L, Mohandas T. Molecular studies of deletions at the human steroid sulfatase locus. Proc Natl Acad Sci USA. 1989;86:8477-8481.
31. Ballabio A, Carrozzo R, Parenti G, et al. Molecular heterogeneity of steroid sulfatase deficiency:a multicenter study on 57 unrelated patients, at DNA and protein levels. Genomics. 1989;4:36-40.
32. Basler E, Grompe M, Parenti G, Yates J, Ballabio A. Identification of point mutations in the steroid sulfatase gene of three patients with X-linked ichthyosis. Am J Hum Genet. 1992;50:483-491.
33. Alperin ES, Shapiro LJ. Characterization of point mutations in patients with X-linked ichthyosis. Effects on the structure and function of the steroid sulfatase protein. J Biol Chem. 1997;272:20756-20763.
34. Sugawara T, Nomura E, Hoshi N. Both N-terminal and C-terminal regions of steroid sulfatase are important for enzyme activity. J Endocrinol. 2006;188:365-374.
35. Reed MJ, Purohit A, Woo LW, Newman SP, Potter BV. Steroid sulfatase:molecular biology, regulation, and inhibition. Endocr Rev. 2005;26:171-202.
36. Recksiek M, Selmer T, Dierks T, Schmidt B, von Figura K. Sulfatases, trapping of the sulfated enzyme intermediate by substituting the active site formylglycine. J Biol Chem. 1998;273:6096-6103.
37. Dierks T, Miech C, Hummerjohann J, Schmidt B, Kertesz MA, von Figura K. Posttranslational formation of formylglycine in prokaryotic sulfatases by modification of either cysteine or serine. J Biol Chem. 1998;273:25560-25564.
38. Preusser-Kunze A, Mariappan M, Schmidt B, et al. Molecular characterization of the human Cα-formylglycinegenerating enzyme. J BiolChem. 2005;280:14900-14910.
39. Zito E, Buono M, Pepe S, et al. Sulfatase modifying factor 1 trafficking through the cells:from endoplasmic reticulum to the endoplasmic reticulum. EMBO J. 2007;26:2443-2453.
40. Cosma MP, Pepe S, Annunziata I, et al. The multiple sulfatase deficiency gene encodes an essential and limiting factor for the activity of sulfatases. Cell. 2003;113:445-456.
41. Dierks T, Schmidt B, Borissenko LV, et al. Multiple sulfatase deficiency is caused by mutations in the gene encoding the human Cα-formylglycine generating enzyme. Cell. 2003;113:435-444.
42. Zito E, Fraldi A, Pepe S, et al. Sulphatase activities are regulated by the interaction of sulphatase-modifying factor 1 with SUMF2. EMBO Rep. 2005;6:655-660.
43. Gande SL, Mariappan M, Schmidt B, Pringle TH, von Figura K, Dierks T. Paralog of the formylglycine-generating enzyme-retention in the endoplasmic reticulum by canonical and noncanonical signals. FEBS J. 2008;275:1118-1130.
44. Willemsen R, Kroos M, Hoogeveen AT, et al. Ultrastructural localization of steroid sulphatase in cultured human fibroblasts by immunocytochemistry:a comparative study with lysosomal enzymes and the mannose 6-phosphate receptor. Histochem J. 1988;20:41-51.
45. Warren JC, French AP. Distribution of steroid sulfatase in human tissues. J Clin Endocrinol Metab. 1965;25:278-282.
46. Dalla Valle L, Toffolo V, Nardi A, et al. The expression of the human steroid sulfatase-encoding gene is driven by alternative first exons. J Steroid Biochem Mol Biol. 2007; 107:22-29.
47. Labrie F. Intracrinology. Mol Cell Endocrinol. 1991;78:C113-C118.
48. Miyakawa I, Kawano Y, Taniyama K, Mori N. Steroid sulfatase activity in human leukocytes. Gynecol Obstet Invest. 1994;38:191-193.
49. Otsuka Y, Yanaihara A, Iwasaki S, Hasegawa J, Yanaihara T, Okai T. Localization and gene expression of steroid sulfatase by RT-PCR in cumulus cells and relationship to serum FSH levels observed during in vitro fertilization. J Exp Clin Assist Reprod. 2005;2:6.
50. Cuevas-Covarrubias SA, Juárez-Oropeza MA, Miranda-Zamora R, Díaz-Zagoya JC. Comparative analysis of human steroid sulfatase activity in prepubertal and postpubertal males and females. Biochem Mol Biol Int. 1993;30:691-695.
51. Li XM, Alperin ES, Salido E, Gong Y, Yen P, Shapiro LJ. Characterization of the promoter region of human steroid sulfatase:a gene which escapes X inactivation. Somat Cell Mol Genet. 1996;22:105-117.
52. Zaichuk T, Ivancic D, Scholtens D, Schiller C, Khan SA. Tissue-specific transcripts of human steroid sulfatase are under control of estrogen signaling pathways in breast carcinoma. J Steroid Biochem Mol Biol. 2007;105:76-84.
53. Prost O, Adessi GL. Estrone and dehydroepiandrosterone sulfatase activities in normal and pathological human endometrium biopsies. J Clin Endocrinol Metab. 1983;56:653-661.
54. MacIndoe JH. The hydrolysis of estrone sulfate and dehydroepiandrosterone sulfate by MCF-7 human breast cancer cells. Endocrinology. 1988;123:1281-1287.
55. Dalla Valle L, Toffolo V, Nardi A, et al. Tissue-specific transcriptional initiation and activity of steroid sulfatase complementing dehydroepiandrosterone sulfate uptake and intracrine steroid activations in human adipose tissue. J Endocrinol. 2006;190:129-139.
56. Fan M, Nakshatri H, Nephew KP. Inhibiting proteasomal proteolysis sustains estrogen receptor-α activation. Mol Endocrinol. 2004;18:2603-2615.
57. Purohit A, Reed MJ, Morris NC, Williams GJ, Potter BV. Regulation and inhibition of steroid sulfatase activity in breast cancer. Ann NY Acad Sci. 1996;784:40-49.
58. Reed MJ, Purohit A. Breast cancer and the role of cytokines in regulating estrogen synthesis:an emerging hypothesis. Endocr Rev. 1997;18:701-715.
59. Suh BY, Jung JJ, Park N, et al. Induction of steroid sulfatase expression by tumor necrosis factor-α through phosphatidylinositol 3-kinase/Akt signaling pathway in PC-3 human prostate cancer cells. Exp Mol Med. 2011;43:646-652.
60. Honma S, Shimodaira K, Shimizu Y, et al. The influence of inflammatory cytokines on estrogen production and cell proliferation in human breast cancer cells. Endocr J. 2002; 49:371-377.
61. Newman SP, Purohit A, Ghilchik MW, Potter BV, Reed MJ. Regulation of steroid sulphatase expression and activity in breast cancer. J Steroid Biochem Mol Biol. 2000; 75:259-264.
62. Purohit A, Newman SP, Reed MJ. The role of cytokines in regulating estrogen synthesis:implications for the etiology of breast cancer. Breast Cancer Res. 2002;4:65-69.
63. Cutolo M, Seriolo B, Villaggio B, Pizzorni C, Craviotto C, Sulli A. Androgens and estrogens modulate the immune and inflammatory responses in rheumatoid arthritis. Ann NY Acad Sci. 2002;966:131-142.
64. Bouman A, Heineman MJ, Faas MM. Sex hormones and the immune response in humans. Hum Reprod Update. 2005;11:411-423.
65. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100:57-70.
66. StraubRH. The complex role of estrogens in inflammation. Endocr Rev. 2007;28:521-574.
67. Nakamura Y, Miki Y, Suzuki T, et al. Steroid sulfatase and estrogen sulfotransferase in the atherosclerotic human aorta. Am J Pathol. 2003;163:1329-1339.
68. Dawson PA. Sulfate in fetal development. Semin Cell Dev Biol. 2011;22:653-659.
69. Imai Y, Yanagishita M, Hascall VC. Measurement of contribution from intracellular cysteine to sulfate in phosphoadenosine phosphosulfate in rat ovarian granulosa cells. Arch Biochem Biophys. 1994;312:392-400.
70. Mueller JW, Shafqat N. Adenosine-5'-phosphosulfate-a multifaceted modulator of bifunctional 3'-phospho-adenosine-5'-phosphosulfate synthases and related enzymes. FEBS J. 2013;280:3050-3057.
71. Markovich D. Na+-sulfate cotransporter SLC13A1. Pflugers Arch. 2014;466:131-137.
72. van den Boom J, Heider D, Martin SR, Pastore A, Mueller JW. 3'-Phosphoadenosine 5'-phosphosulfate (PAPS) synthases, naturally fragile enzymes specifically stabilized by nucleotide binding. J Biol Chem. 2012;287:17645-17655.
73. Hudson BH, Frederick JP, Drake LY, Megosh LC, Irving RP, York JD. Role for cytoplasmic nucleotide hydrolysis in hepatic function and protein synthesis. Proc Natl Acad Sci USA. 2013;110:5040-5045.
74. Hudson BH, York JD. Roles for nucleotide phosphatases in sulfate assimilation and skeletal disease. Adv Biol Regul. 2012;52:229-238.
75. Goettsch S, Badea RA, Mueller JW, et al. Human TPST1 transmembrane domain triggers enzyme dimerisation and localisation to the Golgi compartment. J Mol Biol. 2006; 361:436-449.
76. Hemmerich S, Verdugo D, Rath VL. Strategies for drug discovery by targeting sulfation pathways. Drug Discov Today. 2004;9:967-975.
77. Liu C, Sheng J, Krahn JM, et al. Molecular mechanism of substrate specificity for heparan sulfate 2-O-sulfotransferase. J Biol Chem. 2014;289:13407-13418.
78. MoonAF, XuY, Woody SM, et al. Dissecting the substrate recognition of 3-O-sulfotransferase for the biosynthesis of anticoagulant heparin. Proc Natl Acad SciUSA. 2012;109:5265-5270.
79. Teramoto T, Fujikawa Y, Kawaguchi Y, et al. Crystal structure of human tyrosylprotein sulfotransferase-2 reveals the mechanism of protein tyrosine sulfation reaction. Nat Commun. 2013;4:1572.
80. Liu J, Moon AF, Sheng J, Pedersen LC. Understanding the substrate specificity of the heparan sulfate sulfotransferases by an integrated biosynthetic and crystallographic approach. Curr Opin Struct Biol. 2012;22:550-557.
81. Flicek P, Amode MR, Barrell D, et al. Ensembl 2014. Nucleic Acids Res. 2014;42:D749-D755.
82. Strott CA. Sulfonation and molecular action. Endocr Rev. 2002;23:703-732.
83. Dajani R, Hood AM, CoughtrieMW.A single amino acid, glu146, governs the substrate specificity of a human dopamine sulfotransferase, SULT1A3. Mol Pharmacol. 1998;54:942-948.
84. Hebbring SJ, Adjei AA, Baer JL, et al. Human SULT1A1 gene:copy number differences and functional implications. Hum Mol Genet. 2007;16:463-470.
85. Ridlon JM, Ikegawa S, Alves JM, et al. Clostridium scindens:a human gut microbe with a high potential to convert glucocorticoids into androgens. J Lipid Res. 2013;54:2437-2449.
86. Falany CN. Enzymology of human cytosolic sulfotransferases. FASEB J. 1997;11:206-216.
87. Allali-Hassani A, Pan PW, Dombrovski L, et al. Structural and chemical profiling of the human cytosolic sulfotransferases. PLoS Biol. 2007;5:e97.
88. CookI, WangT, AlmoSC, KimJ, FalanyCN, Leyh TS. Thegate that governs sulfotransferase selectivity. Biochemistry. 2013;52:415-424.
89. Petrotchenko EV, Doerflein ME, Kakuta Y, Pedersen LC, Negishi M. Substrate gating confers steroid specificity to estrogen sulfotransferase. J Biol Chem. 1999;274:30019-30022.
90. Berger I, Guttman C, Amar D, Zarivach R, Aharoni A. The molecular basis for the broad substrate specificity of human sulfotransferase 1A1. PLoS One. 2011;6:e26794.
91. Rehse PH, Zhou M, Lin SX. Crystal structure of human dehydroepiandrosterone sulphotransferase in complex with substrate. Biochem J. 2002;364:165-171.
92. Wang LQ, James MO. Sulfotransferase 2A1 forms estradiol-17-sulfate and celecoxib switches the dominant product from estradiol-3-sulfate to estradiol-17-sulfate. J Steroid Biochem Mol Biol. 2005;96:367-374.
93. Cook IT, Duniec-Dmuchowski Z, Kocarek TA, Runge-Morris M, Falany CN. 24-Hydroxycholesterol sulfation by human cytosolic sulfotransferases:formation of monosulfates and disulfates, molecular modeling, sulfatase sensitivity, and inhibition of liver X receptor activation. Drug Metab Dispos. 2009;37:2069-2078.
94. Hudson BH, York JD. Tissue-specific regulation of 3'-nucleotide hydrolysis and nucleolar architecture. Adv Biol Regul. 2014;54:208-213.
95. Riches Z, Stanley EL, Bloomer JC, Coughtrie MW. Quantitative evaluation of the expression and activity of five major sulfotransferases (SULTs) in human tissues:the SULT "pie". Drug Metab Dispos. 2009;37:2255-2261.
96. Stanley EL, Hume R, CoughtrieMW. Expression profiling of human fetal cytosolic sulfotransferases involved in steroid and thyroid hormone metabolism and in detoxification. Mol Cell Endocrinol. 2005;240:32-42.
97. Duanmu Z, Weckle A, Koukouritaki SB, et al. Developmental expression of aryl, estrogen, and hydroxysteroid sulfotransferases in pre-and postnatal human liver. J Pharmacol Exp Ther. 2006;316:1310-1317.
98. Rainey WE, Nakamura Y. Regulation of the adrenal androgen biosynthesis. J Steroid Biochem Mol Biol. 2008; 108:281-286.
99. Rege J, Nakamura Y, Wang T, Merchen TD, Sasano H, Rainey WE. Transcriptome profiling reveals differentially expressed transcripts between the human adrenal zona fasciculata and zona reticularis. J Clin Endocrinol Metab. 2014;99:E518-E527.
100. JavittNB, LeeYC, ShimizuC, FudaH, StrottCA. Cholesterol and hydroxycholesterol sulfotransferases:identification, distinction from dehydroepiandrosterone sulfotransferase, and differential tissue expression. Endocrinology. 2001;142:2978-2984.
101. Bernstein RM, Sterner KN, Wildman DE. Adrenal androgen production in catarrhine primates and the evolution of adrenarche. Am J Phys Anthropol. 2012;147:389-400.
102. Fuda H, Lee YC, Shimizu C, Javitt NB, Strott CA. Mutational analysis of human hydroxysteroid sulfotransferase SULT2B1 isoforms reveals that exon 1B of the SULT2B1 gene produces cholesterol sulfotransferase, whereas exon 1A yields pregnenolone sulfotransferase. J Biol Chem. 2002;277:36161-36166.
103. Sonoda J, Xie W, Rosenfeld JM, Barwick JL, Guzelian PS, EvansRM. Regulation of a xenobiotic sulfonation cascade by nuclear pregnaneXreceptor (PXR). Proc Natl Acad Sci USA. 2002;99:13801-13806.
104. Kim MS, Shigenaga J, Moser A, Grunfeld C, Feingold KR. Suppression of DHEA sulfotransferase (Sult2A1) during the acute-phase response. AmJ Physiol Endocrinol Metab. 2004;287:E731-E738.
105. Ramaswamy G, Sohn P, Eberhardt A, Serra R. Altered responsiveness to TGF-β results in reduced Papss2 expression and alterations in the biomechanical properties of mouse articular cartilage. Arthritis Res Ther. 2012;14:R49.
106. Kodama S, Negishi M. Sulfotransferase genes:regulation by nuclear receptors in response to xeno/endo-biotics. Drug Metab Rev. 2013;45:441-449.
107. Aleksunes LM, Klaassen CD. Coordinated regulation of hepatic phase I and II drug-metabolizing genes and transporters using AhR-, CAR-, PXR-, PPARα-, and Nrf2-null mice. Drug Metab Dispos. 2012;40:1366-1379.
108. Seo YK, Mirkheshti N, Song CS, et al. SULT2B1b sulfotransferase:induction by vitamin D receptor and reduced expression in prostate cancer. Mol Endocrinol. 2013;27:925-939.
109. Wong S, Tan K, Carey KT, Fukushima A, Tiganis T, Cole TJ. Glucocorticoids stimulate hepatic and renal catecholamine inactivation by direct rapid induction of the dopamine sulfotransferase Sult1d1. Endocrinology. 2010;151:185-194.
110. Gong H, Jarzynka MJ, Cole TJ, et al. Glucocorticoids antagonize estrogens by glucocorticoid receptor-mediated activation of estrogen sulfotransferase. Cancer Res. 2008; 68:7386-7393.
111. Echchgadda I, Song CS, Oh TS, Cho SH, Rivera OJ, Chatterjee B. Gene regulation for the senescence marker protein DHEA-sulfotransferase by the xenobiotic-activated nuclear pregnaneXreceptor (PXR). Mech Ageing Dev. 2004; 125:733-745.
112. Echchgadda I, Song CS, Roy AK, Chatterjee B. Dehydroepiandrosterone sulfotransferase is a target for transcriptional induction by the vitamin D receptor. Mol Pharmacol. 2004;65:720-729.
113. Barrett KG, Fang H, GarganoMD, Markovich D, Kocarek TA, Runge-Morris M. Regulation of murine hepatic hydroxysteroid sulfotransferase expression in hyposulfatemic mice and in a cell model of 3'-phosphoadenosine-5'-phosphosulfate deficiency. Drug Metab Dispos. 2013; 41:1505-1513.
114. Assem M, Schuetz EG, Leggas M, et al. Interactions between hepatic Mrp4 and Sult2a as revealed by the constitutive androstane receptor andMrp4knockout mice. J Biol Chem. 2004;279:22250-22257.
115. Sirianni R, Mayhew BA, Carr BR, Parker CR Jr, Rainey WE. Corticotropin-releasing hormone (CRH) and urocortin act through type 1 CRH receptors to stimulate dehydroepiandrosterone sulfate production in human fetal adrenal cells. J Clin Endocrinol Metab. 2005;90:5393-5400.
116. Saner KJ, Suzuki T, Sasano H, et al. Steroid sulfotransferase 2A1 gene transcription is regulated by steroidogenic factor 1 and GATA-6 in the human adrenal. Mol Endocrinol. 2005;19:184-197.
117. Wang LQ, James MO. Inhibition of sulfotransferases by xenobiotics. Curr Drug Metab. 2006;7:83-104.
118. Kester MH, Bulduk S, van Toor H, et al. Potent inhibition of estrogen sulfotransferase by hydroxylated metabolites of polyhalogenated aromatic hydrocarbons reveals alternative mechanism for estrogenic activity of endocrine disrupters. J Clin Endocrinol Metab. 2002;87:1142-1150.
119. Gosavi RA, Knudsen GA, Birnbaum LS, Pedersen LC. Mimicking of estradiol binding by flame retardants and their metabolites:a crystallographic analysis. Environ Health Perspect. 2013;121:1194-1199.
120. Gulcan HO, Duffel MW. Substrate inhibition in human hydroxysteroid sulfotransferase SULT2A1:studies on the formation of catalytically non-productive enzyme complexes. Arch Biochem Biophys. 2011;507:232-240.
121. Zhang H, Varlamova O, Vargas FM, Falany CN, Leyh TS. Sulfuryl transfer:the catalytic mechanism of human estrogen sulfotransferase. J Biol Chem. 1998;273:10888-10892.
122. Kauffman FC. Sulfonation in pharmacology and toxicology. Drug Metab Rev. 2004;36:823-843.
123. Klaassen CD, Boles JW. Sulfation and sulfotransferases 5:the importance of 3'-phosphoadenosine 5'-phosphosulfate (PAPS) in the regulation of sulfation. FASEB J. 1997;11:404-418.
124. Schröder E, Gebel L, Eremeev AA, et al. Human PAPS synthase isoforms are dynamically regulated enzymes with access to nucleus and cytoplasm. PLoS One. 2012;7:e29559.
125. Grum D, van den Boom J, Neumann D, Matena A, Link NM, Mueller JW. A heterodimer of human 3'-phosphoadenosine-5'-phosphosulphate (PAPS) synthases is a new sulphate activating complex. Biochem Biophys Res Commun. 2010;395:420-425.
126. Roth M, Obaidat A, Hagenbuch B. OATPs, OATs and OCTs:the organic anion and cation transporters of the SLCO and SLC22A gene superfamilies. Br J Pharmacol. 2012;165:1260-1287.
127. Hagenbuch B, Stieger B. The SLCO (former SLC21) superfamily of transporters. Mol Aspects Med. 2013;34:396-412.
128. Koepsell H. TheSLC22family with transporters of organic cations, anions and zwitterions. Mol Aspects Med. 2013; 34:413-435.
129. Cha SH, Sekine T, Kusuhara H, et al. Molecular cloning and characterization of multispecific organic anion transporter 4 expressed in the placenta. J Biol Chem. 2000;275:4507-4512.
130. Sweet DH, Miller DS, Pritchard JB, Fujiwara Y, Beier DR, Nigam SK. Impaired organic anion transport in kidney and choroid plexus of organic anion transporter 3 (Oat3 (Slc22a8)) knockout mice. J BiolChem. 2002;277:26934-26943.
131. Imai Y, Asada S, Tsukahara S, Ishikawa E, Tsuruo T, Sugimoto Y. Breast cancer resistance protein exports sulfated estrogens but not free estrogens. Mol Pharmacol. 2003; 64:610-618.
132. Leuthold S, Hagenbuch B, Mohebbi N, Wagner CA, Meier PJ, Stieger B. Mechanisms of pH-gradient driven transport mediated by organic anion polypeptide transporters. Am J Physiol Cell Physiol. 2009;296:C570-C582.
133. Franco R, Cidlowski JA. SLCO/OATP-like transport of glutathione in FasL-induced apoptosis:glutathione efflux is coupled to an organic anion exchange and is necessary for the progression of the execution phase of apoptosis. J Biol Chem. 2006;281:29542-29557.
134. Li L, Meier PJ, Ballatori N. Oatp2 mediates bidirectional organic solute transport:a role for intracellular glutathione. Mol Pharmacol. 2000;58:335-340.
135. Mahagita C, Grassl SM, Piyachaturawat P, Ballatori N. Humanorganic anion transporter 1B1 and 1B3 function as bidirectional carriers and do not mediate GSH-bile acid cotransport. Am J Physiol Gastrointest Liver Physiol. 2007;293:G271-G278.
136. Kobayashi D, Nozawa T, Imai K, Nezu J, Tsuji A, Tamai I. Involvement of human organic anion transporting polypeptide OATP-B (SLC21A9) in pH-dependent transport across intestinal apical membrane. J Pharmacol Exp Ther. 2003;306:703-708.
137. Nozawa T, Suzuki M, Takahashi K, et al. Involvement of estrone-3-sulfate transporters in proliferation of hormonedependent breast cancer cells. J Pharmacol Exp Ther. 2004;311:1032-1037.
138. Sai Y, Kaneko Y, Ito S, et al. Predominant contribution of organic anion transporting polypeptide OATP-B (OATP2B1) to apical uptake of estrone-3-sulfate by human intestinal Caco-2 cells. Drug Metab Dispos. 2006;34:1423-1431.
139. Varma MV, Rotter CJ, Chupka J, et al. pH-Sensitive interaction of HMG-CoA reductase inhibitors (statins) with organic anion transporting polypeptide 2B1. Mol Pharm. 2011;8:1303-1313.
140. Martinez-Becerra P, Briz O, Romero MR, et al. Further characterization of the electrogenicity andpHsensitivity of the human organic anion-transporting polypeptides OATP1B1and OATP1B3. Mol Pharmacol. 2011;79:596-607.
141. Cole SP, Sparks KE, Fraser K, et al. Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells. Cancer Res. 1994;54:5902-5910.
142. Cole SP. Multidrug resistance protein 1 (MRP1, ABCC1), a "multitasking" ATP-binding cassette (ABC) transporter. J Biol Chem. 2014;289:30880-30888.
143. Su Y, Zhang X, Sinko PJ. Human organic anion-transporting polypeptide OATP-A (SLC21A3) acts in concert with P-glycoprotein and multidrug resistance protein 2 in the vectorial transport of Saquinavir in Hep G2 cells. Mol Pharm. 2004;1:49-56.
144. Sivils JC, Gonzalez I, Bain LJ. Mice lacking Mrp1 have reduced testicular steroid hormone levels and alterations in steroid biosynthetic enzymes. Gen Comp Endocrinol. 2010;167:51-59.
145. Banerjee N, Miller N, Allen C, Bendayan R. Expression of membranetransporters and metabolic enzymes involved in estrone-3-sulphate disposition inhumanbreast tumour tissues. Breast Cancer Res Treat. 2014;145:647-661.
146. Sullivan GF, Yang JM, Vassil A, Yang J, Bash-Babula J, Hait WN. Regulation of expression of the multidrug resistance protein MRP1 by p53 in human prostate cancer cells. J Clin Invest. 2000;105:1261-1267.
147. Hinoshita E, Uchiumi T, Taguchi K, et al. Increased expression of an ATP-binding cassette superfamily transporter, multidrug resistance protein 2, in human colorectal carcinomas. Clin Cancer Res. 2000;6:2401-2407.
148. Qian YM, Song WC, Cui H, Cole SP, Deeley RG. Glutathione stimulates sulfated estrogen transport by multidrug resistance protein 1. J Biol Chem. 2001;276:6404-6411.
149. Zelcer N, Reid G, Wielinga P, et al. Steroid and bile acid conjugates are substrates of human multidrug-resistance protein (MRP) 4 (ATP-binding cassette C4). Biochem J. 2003;371:361-367.
150. Chen ZS, Guo Y, Belinsky MG, Kotova E, Kruh GD. Transport of bile acids, sulfated steroids, estradiol 17-β-D-glucuronide, and leukotriene C4 by human multidrug resistance protein 8 (ABCC11). Mol Pharmacol. 2005;67:545-557.
151. Kruh GD, Guo Y, Hopper-Borge E, Belinsky MG, Chen ZS. ABCC10, ABCC11, and ABCC12. Pflugers Arch. 2007;453:675-684.
152. Bortfeld M, Rius M, König J, Herold-Mende C, Nies AT, Keppler D. Human multidrug resistance protein 8 (MRP8/ABCC11), an apical efflux pump for steroid sulfates, is an axonal protein of the CNS and peripheral nervous system. Neuroscience. 2006;137:1247-1257.
153. Morgan JA, Cheepala SB, Wang Y, et al. Deregulated hepatic metabolism exacerbates impaired testosterone production in Mrp4-deficient mice. J Biol Chem. 2012;287:14456-14466.
154. Abe T, Unno M, Onogawa T, et al. LST-2, a human liverspecific organic anion transporter, determines methotrexate sensitivity in gastrointestinal cancers. Gastroenterology. 2001;120:1689-1699.
155. Lockhart AC, Harris E, Lafleur BJ, et al. Organic anion transporting polypeptide 1B3 (OATP1B3) is overexpressed in colorectal tumors and is a predictor of clinical outcome. Clin Exp Gastroenterol. 2008;1:1-7.
156. Maeda T, Irokawa M, Arakawa H, et al. Uptake transporter organic anion transporting polypeptide 1B3 contributes to the growth of estrogen-dependent breast cancer. J Steroid Biochem Mol Biol. 2010;122:180-185.
157. Hamada A, Sissung T, Price DK, et al. Effect of SLCO1B3 haplotype on testosterone transport and clinical outcome in Caucasian patients with androgen-independent prostatic cancer. Clin Cancer Res. 2008;14:3312-3318.
158. Miyagawa M, Maeda K, Aoyama A, Sugiyama Y. The eighth and ninth transmembrane domains in organic anion transporting polypeptide 1B1 affect the transport kinetics of estrone-3-sulfate and estradiol-17β-D-glucuronide. J Pharmacol Exp Ther. 2009;329:551-557.
159. Li N, Hong W, Huang H, Lu H, Lin G, Hong M. Identification of amino acids essential for estrone-3-sulfate transport within transmembrane domain 2 of organic anion transporting polypeptide 1B1. PLoS One. 2012;7:e36647.
160. Tamai I, Nezu J, Uchino H, et al. Molecular identification and characterization of novel members of the human organic anion transporter (OATP) family. Biochem Biophys Res Commun. 2000;273:251-260.
161. Banerjee N, Allen C, Bendayan R. Differential role of organic anion-transporting polypeptides in estrone-3-sulphate uptake by breast epithelial cells and breast cancer cells. J Pharmacol Exp Ther. 2012;342:510-519.
162. Cui Y, König J, Leier I, Buchholz U, Keppler D. Hepatic uptake of bilirubin and its conjugates by the human organic anion transporter SLC21A6. J BiolChem. 2001;276:9626-9630.
163. Tamai I, Nozawa T, Koshida M, Nezu J, Sai Y, Tsuji A. Functional characterization of human organic anion transporting polypeptide B (OATP-B) in comparison with liverspecific OATP-C. Pharm Res. 2001;18:1262-1269.
164. König J, Cui Y, Nies AT, Keppler D. A novel human organic anion transporting polypeptide localized to the basolateral hepatocyte membrane. AmJ Physiol Gastrointest Liver Physiol. 2000;278:G156-G164.
165. Kullak-Ublick GA, Ismair MG, Stieger B, et al. Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology. 2001;120:525-533.
166. Pizzagalli F, Varga Z, Huber RD, Folkers G, Meier PJ, St-Pierre MV. Identification of steroid sulfate transport processes in the human mammary gland. J Clin Endocrinol Metab. 2003;88:3902-3912.
167. Meyer zu Schwabedissen HE, Tirona RG, Yip CS, Ho RH, Kim RB. Interplay between the nuclear receptor pregnane Xreceptor and the uptake transporter organic anion transporter polypeptide 1A2 selectively enhances estrogen effects in breast cancer. Cancer Res. 2008;68:9338-9347.
168. Pressler H, Sissung TM, Venzon D, Price DK, Figg WD. Expression of OATP family members in hormone-related cancers:potential markers of progression. PLoS One. 2011;6:e20372.
169. Nagai M, Furihata T, Matsumoto S, et al. Identification of a new organic anion transporting polypeptide 1B3 mRNA isoform primarily expressed in human cancerous tissues and cells. Biochem Biophys ResCommun. 2012;418:818-823.
170. Thakkar N, KimK, Jang ER, et al. Acancer-specific variant of the SLCO1B3 gene encodes a novel human organic anion transporting polypeptide 1B3 (OATP1B3) localized mainly in the cytoplasm of colon and pancreatic cancer cells. Mol Pharm. 2013;10:406-416.
171. Nozawa T, Suzuki M, Yabuuchi H, Irokawa M, Tsuji A, Tamai I. Suppression of cell proliferation by inhibition of estrone-3-sulfate transporter in estrogen-dependent breast cancer cells. Pharm Res. 2005;22:1634-1641.
172. Grube M, Köck K, Karner S, et al. Modification of OATP2B1-mediated transport by steroid hormones. Mol Pharmacol. 2006;70:1735-1741.
173. Koenen A, Köck K, Keiser M, Siegmund W, Kroemer HK, Grube M. Steroid hormones specifically modify the activity of organic anion transporting polypeptides. Eur J Pharm Sci. 2012;47:774-780.
174. Grandvuinet AS, Gustavsson L, Steffansen B. Newinsights into the carrier-mediated transport of estrone-3-sulfate in the Caco-2 cell model. Mol Pharm. 2013;10:3285-3295.
175. Kullak-Ublick GA, Fisch T, Oswald M, et al. Dehydroepiandrosterone sulfate (DHEAS):identification of a carrier protein in human liver and brain. FEBS Lett. 1998;424:173-176.
176. Day JM, Purohit A, Tutill HJ, et al. The development of steroid sulfatase inhibitors for hormone-dependent cancer therapy. Ann NY Acad Sci. 2009;1155:80-87.
177. Longcope C. Metabolism of dehydroepiandrosterone. Ann NY Acad Sci. 1995;774:143-148.
178. Wright JL, Kwon EM, Ostrander EA, et al. Expression ofSLCO transport genes in castration-resistant prostate cancer and impact of genetic variation in SLCO1B3 and SLCO2B1on prostate cancer outcomes. Cancer Epidemiol Biomarkers Prev. 2011;20:619-627.
179. Arakawa H, Nakanishi T, Yanagihara C, et al. Enhanced expression of organic anion transporting polypeptides (OATPs) in androgen receptor-positive prostate cancer cells:possible role of OATP1A2 in adaptive cell growth under androgen-depleted conditions. Biochem Pharmacol. 2012;84:1070-1077.
180. Ugele B, BahnA, Rex-HaffnerM. Functional differences in steroid sulfate uptake of organic anion transporter 4 (OAT4) and organic anion transporting polypeptide 2B1 (OATP2B1) in human placenta. J Steroid Biochem Mol Biol. 2008;111:1-6.
181. Grube M, Reuther S, Meyer Zu Schwabedissen H, et al. Organic anion transporting polypeptide 2B1 and breast cancer resistance protein interact in the transepithelial transport of steroid sulfates in human placenta. Drug Metab Dispos. 2007;35:30-35.
182. Cho E, Montgomery RB, Mostaghel EA. Minireview:SLCO andABCtransporters:a role for steroid transport in prostate cancer progression. Endocrinology. 2014;155:4124-4132.
183. Nozawa T, Minami H, Sugiura S, Tsuji A, Tamai I. Role of organic anion transporter OATP1B1 (OATP-C) in hepatic uptake of irinotecan and its active metabolite, 7-ethyl-10-hydroxycamptothecin:in vitro evidence and effect of single nucleotide polymorphisms. Drug Metab Dispos. 2005;33:434-439.
184. Nozawa T, Nakajima M, Tamai I, et al. Genetic polymorphisms of human organic anion transporters OATP-C (SLC21A6) and OATP-B (SLC21A9):allele frequencies in the Japanese population and functional analysis. J Pharmacol Exp Ther. 2002;302:804-813.
185. Yang M, Xie W, Mostaghel E, et al. SLCO2B1 and SLCO1B3 may determine time to progression for patients receiving androgen deprivation therapy for prostate cancer. J Clin Oncol. 2011;29:2565-2573.
186. Fujimoto N, Kubo T, Inatomi H, et al. Polymorphisms of the androgen transporting gene SLCO2B1 may influence the castration resistance of prostate cancer and the racial differences in response to androgen deprivation. Prostate Cancer Prostatic Dis. 2013;16:336-340.
187. Jung D, Kullak-Ublick GA. Hepatocyte nuclear factor 1 α:a key mediator of the effect of bile acids on gene expression. Hepatology. 2003;37:622-631.
188. Furihata T, Satoh T, YamamotoN, Kobayashi K, Chiba K. Hepatocyte nuclear factor 1α is a factor responsible for the interindividual variation of OATP1B1 mRNA levels in adult Japanese livers. Pharm Res. 2007;24:2327-2332.
189. Wood M, Ananthanarayanan M, Jones B, et al. Hormonal regulation of hepatic organic anion transporting polypeptides. Mol Pharmacol. 2005;68:218-225.
190. Le Vee M, Lecureur V, Stieger B, Fardel O. Regulation of drug transporter expression in human hepatocytes exposed to the proinflammatory cytokines tumor necrosis factor-α or interleukin-6. Drug Metab Dispos. 2009;37:685-693.
191. Le Vee M, Gripon P, Stieger B, Fardel O. Down-regulation of organic anion transporter expression in human hepatocytes exposed to the proinflammatory cytokine interleukin 1β. Drug Metab Dispos. 2008;36:217-222.
192. Kullak-Ublick GA, Beuers U, Fahney C, Hagenbuch B, Meier PJ, Paumgartner G. Identification and functional characterization of the promoter region of the human organic anion transporting polypeptide gene. Hepatology. 1997;26:991-997.
193. Miki Y, Suzuki T, Kitada K, et al. Expression of the steroid and xenobiotic receptor and its possible target gene, organic anion transporting polypeptide-A, in human breast carcinoma. Cancer Res. 2006;66:535-542.
194. Fernandes NF, Janniger CK, Schwartz RA. X-linked ichthyosis:an oculocutaneous genodermatosis. J Am Acad Dermatol. 2010;62:480-485.
195. Bonifas JM, Morley BJ, Oakey RE, Kan YW, Epstein EH Jr. Cloning of a cDNA for steroid sulfatase:frequent occurrence of gene deletions in patients with recessiveXchromosome-linked ichthyosis. Proc Natl Acad Sci USA. 1987; 84:9248-9251.
196. Wells RS, Kerr CB. Clinical features of autosomal dominant and sex-linked ichthyosis in an English population. Br Med J. 1966;1:947-950.
197. Ingordo V, D'Andria G, Gentile C, Decuzzi M, Mascia E, Naldi L. Frequency of X-linked ichthyosis in coastal southern Italy:a study on a representative sample of a young male population. Dermatology. 2003;207:148-150.
198. Craig WY, Roberson M, Palomaki GE, Shackleton CH, Marcos J, Haddow JE. Prevalence of steroid sulfatase deficiency in California according to race and ethnicity. Prenat Diagn. 2010;30:893-898.
199. Wells RS, Kerr CB. Genetic classification of ichthyosis. Arch Dermatol. 1965;92:1-6.
200. Elias PM, Williams ML, Maloney ME, et al. Stratum corneum lipids in disorders of cornification. Steroid sulfatase and cholesterol sulfate in normal desquamation and the pathogenesis of recessive X-linked ichthyosis. J Clin Invest. 1984;74:1414-1421.
201. Williams ML. Epidermal lipids and scaling diseases of the skin. Semin Dermatol. 1992;11:169-175.
202. Williams ML, Elias PM. Stratum corneum lipids in disorders of cornification:increased cholesterol sulfate content of stratum corneum in recessive x-linked ichthyosis. J Clin Invest. 1981;68:1404-1410.
203. Traupe H, Ropers HH. Cryptorchidism and hypogenitalism in X-linked recessive ichthyosis vulgaris. Hum Genet. 1982;60:206.
204. Harkness RA. Current clinical problems in placental steroid or aryl sulphatase C deficiency and the related 'cervical dystocia' and X-linked ichthyosis. J Inherit Metab Dis. 1982;5:142-144.
205. Traupe H, Happle R. Clinical spectrum of steroid sulfatase deficiency:X-linked recessive ichthyosis, birth complications and cryptorchidism. Eur J Pediatr. 1983;140:19-21.
206. Lykkesfeldt G, Müller J, Skakkebaek NE, Bruun E, Lykkesfeldt AE. Absence of testicular steroid sulphatase activity in a boy with recessive X-linked ichthyosis and testicular maldescent. Eur J Pediatr. 1985;144:273-274.
207. Bradshaw KD, Carr BR. Placental sulfatase deficiency:maternal and fetal expression of steroid sulfatase deficiency and X-linked ichthyosis. Obstet Gynecol Surv. 1986;41:401-413.
208. Lynch HT, Ozer F, McNutt CW, Johnson JE, Jampolsky NA. Secondary male hypogonadism and congenital ichthyosis:association of two rare genetic diseases. AmJHum Genet. 1960;12:440-447.
209. Toppari J, Kaleva M. Maldescendus testis. Horm Res. 1999;51:261-269.
210. Lykkesfeldt G, Høyer H, Lykkesfeldt AE, Skakkebaek NE. Steroid sulphatase deficiency associated with testis cancer. Lancet. 1983;2:1456.
211. Zuidema LJ, Khan-Dawood F, Dawood MY, Work BA Jr. Hormones and cervical ripening:dehydroepiandrosterone sulfate, estradiol, estriol, and progesterone. Am J Obstet Gynecol. 1986;155:1252-1254.
212. France JT, Liggins GC. Placental sulfatase deficiency. J Clin Endocrinol Metab. 1969;29:138-141.
213. Attenburrow AA, Heslip M, Henderson MJ, Holton JB, Scott IV, Arthur LJ. Placental steroid sulphatase deficiency. Arch Dis Child. 1984;59:1187-1189.
214. Rizk DE, Johansen KA. Placental sulfatase deficiency and congenital ichthyosis with intrauterine fetal death:case report. Am J Obstet Gynecol. 1993;168:570-571.
215. Glass IA, Lam RC, Chang T, Roitman E, Shapiro LJ, Shackleton CH. Steroid sulphatase deficiency is the major cause of extremely low oestriol production at mid-pregnancy:a urinary steroid assay for the discrimination of steroid sulphatase deficiency from other causes. Prenat Diagn. 1998;18:789-800.
216. Shackleton CH. Role of a disordered steroid metabolome in the elucidation of sterol and steroid biosynthesis. Lipids. 2012;47:1-12.
217. Reisch N, Idkowiak J, Hughes BA, et al. Prenatal diagnosis of congenital adrenal hyperplasia caused by P450 oxidoreductase deficiency. J Clin Endocrinol Metab. 2013; 98:E528-E536.
218. Delfino M, Procaccini EM, Illiano GM, Milone A. X-linked ichthyosis:relation between cholesterol sulphate, dehydroepiandrosterone sulphate and patient's age. Br J Dermatol. 1998;138:655-657.
219. Milone A, Delfino M, Piccirillo A, Illiano GM, Aloj SM, Bifulco M. Increased levels of DHEAS in serum of patients with X-linked ichthyosis. J Inherit Metab Dis. 1991;14:96-104.
220. Bergner EA, Shapiro LJ. Metabolism of 3H-dehydroepiandrosterone sulphate by subjects with steroid sulphatase deficiency. J Inherit Metab Dis. 1988;11:403-415.
221. Lykkesfeldt G, Bennett P, Lykkesfeldt AE, Micic S, Møller S, Svenstrup B. Abnormal androgen and oestrogen metabolism in men with steroid sulphatase deficiency and recessive X-linked ichthyosis. Clin Endocrinol (Oxf). 1985;23:385-393.
222. Ruokonen A, Oikarinen A, Palatsi R, Huhtaniemi I. Serum steroid sulphates in ichthyosis. Br J Dermatol. 1980;103:245-248.
223. Hammer F, Subtil S, Lux P, et al. No evidence for hepatic conversion of dehydroepiandrosterone (DHEA) sulfate to DHEA:in vivo and in vitro studies. J Clin Endocrinol Metab. 2005;90:3600-3605.
224. Lindberg MC, McClenaghan C, Herrmann WL. Fate of injected dehydroisoandrosterone, testosterone, and dehydroiisoandrosterone sulfate in plasma in the human. Am J Obstet Gynecol. 1966;95:743-746.
225. Schlotawa L, Ennemann EC, Radhakrishnan K, et al. SUMF1 mutations affecting stability and activity of formylglycine generating enzyme predict clinical outcome in multiple sulfatase deficiency. Eur J Hum Genet. 2011;19:253-261.
226. Schlotawa L, Radhakrishnan K, Baumgartner M, et al. Rapid degradation of an active formylglycine generating enzyme variant leads to a late infantile severe form of multiple sulfatase deficiency. Eur J Hum Genet. 2013;21:1020-1023.
227. Dierks T, Schlotawa L, Frese MA, Radhakrishnan K, von Figura K, Schmidt B. Molecular basis of multiple sulfatase deficiency, mucolipidosis II/III and Niemann-Pick C1 disease-Lysosomal storage disorders caused by defects of non-lysosomal proteins. Biochim Biophys Acta. 2009; 1793:710-725.
228. Kent L, Emerton J, Bhadravathi V, et al. X-Linked ichthyosis (steroid sulfatase deficiency) is associated with increased risk of attention deficit hyperactivity disorder, autism and social communication deficits. J Med Genet. 2008;45:519-524.
229. Brookes KJ, Hawi Z, Kirley A, Barry E, Gill M, Kent L. Association of the steroid sulfatase (STS) gene with attention deficit hyperactivity disorder. AmJMedGenetBNeuropsychiatr Genet. 2008;147B:1531-1535.
230. Davies W, Humby T, Trent S, Eddy JB, Ojarikre OA, Wilkinson LS. Genetic and pharmacological modulation of the steroid sulfatase axis improves response control; comparison with drugs used in ADHD. Neuropsychopharmacology. 2014;39:2622-2632.
231. Davies W, Humby T, Kong W, Otter T, Burgoyne PS, Wilkinson LS. Converging pharmacological and genetic evidence indicates a role for steroid sulfatase in attention. Biol Psychiatry. 2009;66:360-367.
232. Mizumoto S, Ikegawa S, Sugahara K. Human genetic disorders caused by mutations in genes encoding biosynthetic enzymes for sulfated glycosaminoglycans. J Biol Chem. 2013;288:10953-10961.
233. Kurima K, Warman ML, Krishnan S, et al. A member of a family of sulfate-activating enzymes causes murine brachymorphism. Proc Natl Acad SciUSA. 1998;95:8681-8685.
234. Orkin RW, Pratt RM, Martin GR. Undersulfated chondroitin sulfate in the cartilage matrix of brachymorphic mice. Dev Biol. 1976;50:82-94.
235. Faiyaz ul Haque M, King LM, Krakow D, et al. Mutations in orthologous genes in human spondyloepimetaphyseal dysplasia and the brachymorphic mouse. Nat Genet. 1998; 20:157-162.
236. Ahmad M, Faiyaz Ul Haque M, Ahmad W, et al. Distinct, autosomal recessive form of spondyloepimetaphyseal dysplasia segregating in an inbred Pakistani kindred. Am J Med Genet. 1998;78:468-473.
237. Noordam C, Dhir V, McNelis JC, et al. Inactivating PAPSS2 mutations in a patient with premature pubarche. N Engl J Med. 2009;360:2310-2318.
238. Oostdijk W, Idkowiak J, Mueller JW, et al. PAPSS2 deficiency causes androgen excess via impaired DHEA sulfation-in vitro and in vivo studies in a family harboring two novel PAPSS2 mutations. J Clin Endocrinol Metab. 2015:100:E672-E680.
239. Thiele H, Sakano M, Kitagawa H, et al. Loss of chondroi-tin 6-O-sulfotransferase-1 function results in severehuman chondrodysplasia with progressive spinal involvement. Proc Natl Acad Sci USA. 2004;101:10155-10160.
240. Hermanns P, Unger S, Rossi A, et al. Congenital joint dislocations caused by carbohydrate sulfotransferase 3 deficiency in recessive Larsen syndrome and humero-spinal dysostosis. Am J Hum Genet. 2008;82:1368-1374.
241. Cortes M, Baria AT, Schwartz NB. Sulfation of chondroitin sulfate proteoglycans is necessary for proper Indian hedgehog signaling in the developing growth plate. Development. 2009;136:1697-1706.
242. Frederick JP, Tafari AT, WuSM, et al. Arole for a lithiuminhibited Golgi nucleotidase in skeletal development and sulfation. Proc Natl Acad Sci USA. 2008;105:11605-11612.
243. Vissers LE, Lausch E, Unger S, et al. Chondrodysplasia and abnormal joint development associated with mutations in IMPAD1, encoding the Golgi-resident nucleotide phosphatase, gPAPP. Am J Hum Genet. 2011;88:608-615.
244. Nizon M, Alanay Y, Tuysuz B, et al. IMPAD1 mutations in two Catel-Manzke like patients. Am J Med Genet A. 2012;158A:2183-2187.
245. Goodarzi MO, Carmina E, Azziz R. DHEA, DHEAS and PCOS. J Steroid Biochem Mol Biol. 2015;145:213-225.
246. O'Reilly MW, Taylor AE, Crabtree NJ, et al. Hyperandrogenemia predicts metabolic phenotype in polycystic ovary syndrome:the utility of serum androstenedione. J Clin Endocrinol Metab. 2014;99:1027-1036.
247. Goodarzi MO, Antoine HJ, Azziz R. Genes for enzymes regulating dehydroepiandrosterone sulfonation are associated with levels of dehydroepiandrosterone sulfate in polycystic ovary syndrome. J Clin Endocrinol Metab. 2007;92:2659-2664.
248. Louwers YV, de Jong FH, van Herwaarden NA, et al. Variants in SULT2A1 affect theDHEAsulphate toDHEAratio in patients with polycystic ovary syndrome but not the hyperandrogenic phenotype. J Clin Endocrinol Metab. 2013;98:3848-3855.
249. Haring R, Wallaschofski H, Teumer A, et al. A SULT2A1 genetic variant identified by GWAS as associated with low serum DHEAS does not impact on the actual DHEA/DHEAS ratio. J Mol Endocrinol. 2013;50:73-77.
250. Iida A, Simsek-Kiper Pö, Mizumoto S, et al. Clinical and radiographic features of the autosomal recessive form of brachyolmia caused by PAPSS2 mutations. Hum Mutat. 2013;34:1381-1386.
251. Quinkler M, Sinha B, Tomlinson JW, Bujalska IJ, Stewart PM, Arlt W. Androgen generation in adipose tissue in women with simple obesity-a site-specific role for 17β-hydroxysteroid dehydrogenase type 5. J Endocrinol. 2004; 183:331-342.
252. Ihunnah CA, Wada T, Philips BJ, et al. Estrogen sulfotransferase/SULT1E1 promotes human adipogenesis. Mol Cell Biol. 2014;34:1682-1694.
253. Khor VK, Dhir R, Yin X, Ahima RS, Song WC. Estrogen sulfotransferase regulates body fat and glucose homeostasis in female mice. Am J Physiol Endocrinol Metab. 2010; 299:E657-E664.
254. Wada T, Ihunnah CA, Gao J, et al. Estrogen sulfotransferase inhibits adipocyte differentiation. Mol Endocrinol. 2011;25:1612-1623.
255. Jones ME, Thorburn AW, Britt KL, et al. Aromatase-deficient (ArKO) mice have a phenotype of increased adiposity. Proc Natl Acad Sci USA. 2000;97:12735-12740.
256. Heine PA, Taylor JA, Iwamoto GA, Lubahn DB, Cooke PS. Increased adipose tissue in male and female estrogen receptor-α knockout mice. Proc Natl Acad Sci USA. 2000; 97:12729-12734.
257. Ribas V, Nguyen MT, Henstridge DC, et al. Impaired oxidative metabolism and inflammation are associated with insulin resistance in ERα-deficient mice. Am J Physiol Endocrinol Metab. 2010;298:E304-E319.
258. Riant E, Waget A, Cogo H, Arnal JF, Burcelin R, Gourdy P. Estrogens protect against high-fat diet-induced insulin resistance and glucose intolerance in mice. Endocrinology. 2009;150:2109-2117.
259. Gao H, Bryzgalova G, Hedman E, et al. Long-term administration of estradiol decreases expression of hepatic lipogenic genes and improves insulin sensitivity in ob/ob mice:a possible mechanism is through direct regulation of signal transducer and activator of transcription 3. Mol Endocrinol. 2006;20:1287-1299.
260. Gao J, He J, Shi X, et al. Sex-specific effect of estrogen sulfotransferase on mouse models of type 2 diabetes. Diabetes. 2012;61:1543-1551.
261. Jiang M, He J, Kucera H, et al. Hepatic overexpression of steroid sulfatase ameliorates mouse models of obesity and type 2 diabetes through sex-specific mechanisms. J Biol Chem. 2014;289:8086-8097.
262. Janowski BA, Willy PJ, Devi TR, Falck JR, Mangelsdorf DJ. An oxysterol signalling pathway mediated by the nuclear receptor LXR α. Nature. 1996;383:728-731.
263. Uppal H, Saini SP, Moschetta A, et al. Activation of LXRs prevents bile acid toxicity and cholestasis in female mice. Hepatology. 2007;45:422-432.
264. Ahn SB, Jang K, Jun DW, Lee BH, Shin KJ. Expression of liver X receptor correlates with intrahepatic inflammation and fibrosis in patients with nonalcoholic fatty liver disease. Dig Dis Sci. 2014;59:2975-2982.
265. Ren S, Ning Y. Sulfation of 25-hydroxycholesterol regulates lipid metabolism, inflammatory responses, and cell proliferation. Am J Physiol Endocrinol Metab. 2014;306:E123-E130.
266. Saini SP, Sonoda J, Xu L, et al. A novel constitutive androstane receptor-mediated and CYP3A-independent pathway of bile acid detoxification. Mol Pharmacol. 2004; 65:292-300.
267. Li X, Pandak WM, Erickson SK, et al. Biosynthesis of the regulatory oxysterol, 5-cholesten-3β, 25-diol 3-sulfate, in hepatocytes. J Lipid Res. 2007;48:2587-2596.
268. Polyzos SA, Kountouras J, Mantzoros CS. Sulfated oxysterols as candidates for the treatment of nonalcoholic fatty liver disease. Metabolism. 2012;61:755-758.
269. Purohit A, Foster PA. Steroid sulfatase inhibitors for estrogen-and androgen-dependent cancers. J Endocrinol. 2012;212:99-110.
270. Chetrite GS, Cortes-Prieto J, Philippe JC, Wright F, Pasqualini JR. Comparison of estrogen concentrations, estrone sulfatase and aromatase activities in normal, and in cancerous, human breast tissues. J Steroid Biochem Mol Biol. 2000;72:23-27.
271. Kirschner MA, Cohen FB, Ryan C. Androgen-estrogenproduction rates in postmenopausal women with breast cancer. Cancer Res. 1978;38:4029-4035.
272. Geisler J, Suzuki T, Helle H, et al. Breast cancer aromatase expression evaluated by the novel antibody 677:correlations to intra-tumor estrogen levels and hormone receptor status. J Steroid Biochem Mol Biol. 2010;118:237-241.
273. Pasqualini JR, Chetrite G, Blacker C, et al. Concentrations of estrone, estradiol, and estrone sulfate and evaluation of sulfatase and aromatase activities in pre-and postmenopausal breast cancer patients. J Clin Endocrinol Metab. 1996;81:1460-1464.
274. Suzuki M, Ishida H, Shiotsu Y, et al. Expression level of enzymes related to in situ estrogen synthesis and clinicopathological parameters in breast cancer patients. J Steroid Biochem Mol Biol. 2009;113:195-201.
275. Santner SJ, Feil PD, Santen RJ. In situ estrogen production via the estrone sulfatase pathway in breast tumors:relative importance versus the aromatase pathway. J Clin Endocrinol Metab. 1984;59:29-33.
276. WoodPM, WooLW, Thomas MP, Mahon MF, Purohit A, Potter BV. Aromatase and dual aromatase-steroid sulfatase inhibitors from the letrozole and vorozole templates. Chem Med Chem. 2011;6:1423-1438.
277. Tsunoda Y, Shimizu Y, Tsunoda A, Takimoto M, Sakamoto MA, Kusano M. Steroid sulfatase in breast carcinoma and change of serum estrogens levels after operation. Acta Oncol. 2006;45:584-589.
278. Utsumi T, Yoshimura N, Takeuchi S, Maruta M, Maeda K, Harada N. Elevated steroid sulfatase expression in breast cancers. J Steroid Biochem Mol Biol. 2000;73:141-145.
279. Al Sarakbi W, Mokbel R, Salhab M, Jiang WG, Reed MJ, Mokbel K. The role of STS andOATP-BmRNAexpression in predicting the clinical outcome in human breast cancer. Anticancer Res. 2006;26:4985-4990.
280. Miyoshi Y, Ando A, Hasegawa S, et al. High expression of steroid sulfatase mRNA predicts poor prognosis in patients with estrogen receptor-positive breast cancer. Clin Cancer Res. 2003;9:2288-2293.
281. Irahara N, Miyoshi Y, Taguchi T, Tamaki Y, Noguchi S. Quantitative analysis of aromatase, sulfatase and 17β-HSD(1) mRNA expression in soft tissue metastases of breast cancer. Cancer Lett. 2006;243:23-31.
282. McNamara KM, Sasano H. The intracrinology of breast cancer. J Steroid Biochem Mol Biol. 2015;145:172-178.
283. Hudelist G, Wülfing P, Kersting C, et al. Expression of aromatase and estrogen sulfotransferase in preinvasive and invasive breast cancer. J Cancer Res Clin Oncol. 2008; 134:67-73.
284. Blankenstein MA, van de Ven J, Maitimu-Smeele I, et al. Intratumoral levels of estrogens in breast cancer. J Steroid Biochem Mol Biol. 1999;69:293-297.
285. Chanplakorn N, Chanplakorn P, Suzuki T, et al. Increased estrogen sulfatase (STS) and 17β-hydroxysteroid dehydrogenase type 1(17β-HSD1) following neoadjuvant aromatase inhibitor therapy in breast cancer patients. Breast Cancer Res Treat. 2010;120:639-648.
286. Haynes BP, Straume AH, Geisler J, et al. Intratumoral estrogen disposition in breast cancer. Clin Cancer Res. 2010; 16:1790-1801.
287. Hanamura T, Niwa T, Gohno T, et al. Possible role of the aromatase-independent steroid metabolism pathways in hormone responsive primary breast cancers. Breast Cancer Res Treat. 2014;143:69-80.
288. Utsumi T, Yoshimura N, Takeuchi S, Ando J, Maruta M, Maeda K, Harada N. Steroid sulfatase expression is an independent predictor of recurrence in human breast cancer. Cancer Res. 1999;59:377-381.
289. Takagi K, Moriya T, Kurosumi M, et al. Intratumoral estrogen concentration and expression of estrogen-induced genes in male breast carcinoma:comparison with female breast carcinoma. Horm Cancer. 2013;4:1-11.
290. Adair FE, Herrmann JB. The use of testosterone propionate in the treatment of advanced carcinoma of the breast. Ann Surg. 1946;123:1023-1035.
291. Goldenberg IS, Sedransk N, Volk H, SegaloffA, Kelley RM, Haines CR. Combined androgen and antimetabolite therapy of advanced female breast cancer. A report of the cooperative breast cancer group. Cancer. 1975;36:308-310.
292. Ortmann J, Prifti S, Bohlmann MK, Rehberger-Schneider S, Strowitzki T, Rabe T. Testosterone and 5 α-dihydrotestosterone inhibit in vitro growth of human breast cancer cell lines. Gynecol Endocrinol. 2002;16:113-120.
293. Birrell SN, Bentel JM, Hickey TE, et al. Androgens induce divergent proliferative responses in human breast cancer cell lines. J Steroid Biochem Mol Biol. 1995;52:459-467.
294. McNamara KM, Moore NL, Hickey TE, Sasano H, Tilley WD. Complexities of androgen receptor signalling in breast cancer. Endocr Relat Cancer. 2014;21:T161-T181.
295. Vera-Badillo FE, Templeton AJ, de Gouveia P, et al. Androgen receptor expression and outcomes in early breast cancer:a systematic review and meta-analysis [published online November 22, 2013]. J Natl Cancer Inst. doi:10.1093/jnci/djt319.
296. Key TJ, Appleby PN, Reeves GK, et al. Sex hormones and risk of breast cancer in premenopausal women:a collaborative reanalysis of individual participant data from seven prospective studies. Lancet Oncol. 2013;14:1009-1019.
297. Fortner RT, Eliassen AH, Spiegelman D, Willett WC, Barbieri RL, Hankinson SE. Premenopausal endogenous steroid hormones and breast cancer risk:results from the Nurses' Health Study II. Breast Cancer Res. 2013;15:R19.
298. Zhang X, Tworoger SS, Eliassen AH, Hankinson SE. Postmenopausal plasma sex hormone levels and breast cancer risk over 20 years of follow-up. Breast Cancer Res Treat. 2013;137:883-892.
299. Key TJ, Appleby PN, Reeves GK, et al. Circulating sex hormones and breast cancer risk factors in postmenopausal women:reanalysis of 13 studies. Br J Cancer. 2011; 105:709-722.
300. Bhattacharyya S, Tobacman JK. Steroid sulfatase, arylsulfatases A and B, galactose-6-sulfatase, and iduronate sulfatase in mammary cells and effects of sulfated and nonsulfated estrogens on sulfatase activity. J Steroid Biochem Mol Biol. 2007;103:20-34.
301. Calhoun KE, Pommier RF, Muller P, Fletcher WS, Toth-Fejel S. Dehydroepiandrosterone sulfate causes proliferation of estrogen receptor-positive breast cancer cells despite treatment with fulvestrant. Arch Surg. 2003;138:879-883.
302. Le Bail JC, LotfiH, Charles L, Pépin D, Habrioux G. Con-version of dehydroepiandrosterone sulfate at physiological plasma concentration into estrogens in MCF-7 cells. Steroids. 2002;67:1057-1064.
303. Gayosso V, Montano LF, López-Marure R. DHEA-induced antiproliferative effect in MCF-7 cells is androgenand estrogen receptor-independent. Cancer J. 2006;12:160-165.
304. López-Marure R, Contreras PG, Dillon JS. Effects of dehydroepiandrosterone on proliferation, migration, and death of breast cancer cells. Eur J Pharmacol. 2011;660:268-274.
305. Ishida H, Nakata T, Suzuki M, et al. A novel steroidal selective steroid sulfatase inhibitor KW-2581 inhibits sulfated-estrogen dependent growth of breast cancer cells in vitro and in animal models. Breast Cancer Res Treat. 2007; 106:215-227.
306. Purohit A, Woo LW, Potter BV, Reed MJ. In vivo inhibition of estrone sulfatase activity and growth of nitrosomethylurea-induced mammary tumors by 667 COUMATE. Cancer Res. 2000;60:3394-3396.
307. Stanway SJ, Purohit A, WooLW, et al. Phase I study ofSTX 64 (667 Coumate) in breast cancer patients:the first study of a steroid sulfatase inhibitor. Clin Cancer Res. 2006;12:1585-1592.
308. Roddam AW, Allen NE, Appleby P, Key TJ. Endogenous sex hormones and prostate cancer:a collaborative analysis of 18 prospective studies. J Natl Cancer Inst. 2008;100:170-183.
309. Huggins C, Scott WW. Bilateral adrenalectomy in prostatic cancer. Ann Surg. 1945;122:1031-1041.
310. Harper ME, Pike A, Peeling WB, Griffiths K. Steroids of adrenal origin metabolized by human prostatic tissue both in vivo and in vitro. J Endocrinol. 1974;60:117-125.
311. Farnsworth WE. Human prostatic dehydroepiandrosterone sulfate sulfatase. Steroids. 1973;21:647-664.
312. Nakamura Y, Suzuki T, Fukuda T, et al. Steroid sulfatase and estrogen sulfotransferase in human prostate cancer. Prostate. 2006;66:1005-1012.
313. Meloche CA, Falany CN. Expression and characterization of the human 3 β-hydroxysteroid sulfotransferases (SULT2B1a and SULT2B1b). J Steroid Biochem Mol Biol. 2001;77:261-269.
314. Selcer KW, Kabler H, Sarap J, Xiao Z, Li PK. Inhibition of steryl sulfatase activity in LNCaP human prostate cancer cells. Steroids. 2002;67:821-826.
315. Anagnostopoulou V, Pediaditakis I, Alkahtani S, et al. Differential effects of dehydroepiandrosterone and testosterone in prostate and colon cancer cell apoptosis:the role of nerve growth factor (NGF) receptors. Endocrinology. 2013;154:2446-2456.
316. Roy J, Lefebvre J, Maltais R, Poirier D. Inhibition of dehydroepiandrosterone sulfate action in androgen-sensitive tissues by EM-1913, an inhibitor of steroid sulfatase. Mol Cell Endocrinol. 2013;376:148-155.
317. Mizokami A, Koh E, Izumi K, et al. Prostate cancer stromal cells and LNCaP cells coordinately activate the androgen receptor through synthesis of testosterone and dihydrotestosterone from dehydroepiandrosterone. Endocr Relat Cancer. 2009;16:1139-1155.
318. Arnold JT, Gray NE, Jacobowitz K, et al. Human prostate stromal cells stimulate increased PSA production in DHEA-treated prostate cancer epithelial cells. J Steroid Biochem Mol Biol. 2008;111:240-246.
319. Tamae D, Mostaghel E, Montgomery B, et al. The DHEAsulfate depot following P450c17 inhibition supports the case for AKR1C3 inhibition in high risk localized and advanced castration resistant prostate cancer. Chem Biol Interact. 2015;234:332-338.
320. Stanczyk FZ, Azen CG, Pike MC. Effect of finasteride on serum levels of androstenedione, testosterone and their 5α-reduced metabolites in men at risk for prostate cancer. J Steroid Biochem Mol Biol. 2013;138:10-16.
321. Lokhov PG, Dashtiev MI, Bondartsov LV, Lisitsa AV, Moshkovskiĭ SA, Archakov AI. Metabolic fingerprinting of blood plasma for patients with prostate cancer [in Russian]. Biomed Khim. 2009;55:247-254.
322. Christoforou P, Christopoulos PF, KoutsilierisM. The role of estrogen receptor β in prostate cancer. Mol Med. 2014; 20:427-434.
323. Grubisha MJ, DeFranco DB. Local endocrine, paracrine and redox signaling networks impact estrogen and androgen crosstalk in the prostate cancer microenvironment. Steroids. 2013;78:538-541.
324. Giton F, Sirab N, Franck G, et al. Evidence of estronesulfate uptake modification in young and middle-aged rat prostate. J Steroid Biochem Mol Biol. 2015;152:89-100.
325. Abd Elmageed ZY, Moroz K, Srivastav SK, et al. High circulating estrogens and selective expression of ERβ in prostate tumors of Americans:implications for racial disparity of prostate cancer. Carcinogenesis. 2013;34:2017-2023.
326. He D, Falany CN. Inhibition of SULT2B1b expression alters effects of 3β-hydroxysteroids on cell proliferation and steroid hormone receptor expression in human LNCaP prostate cancer cells. Prostate. 2007;67:1318-1329.
327. Sung CH, Im HJ, Park N, et al. Induction of steroid sulfatase expression in PC-3 human prostate cancer cells by insulin-like growth factor II. Toxicol Lett. 2013;223:109-115.
328. Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420:860-867.
329. Jiang J, Li J, Yunxia Z, Zhu H, Liu J, Pumill C. The role of prostatitis in prostate cancer:meta-analysis. PLoS One. 2013;8:e85179.
330. Sharma J, Gray KP, Harshman LC, et al. Elevated IL-8, TNF-α, andMCP-1in men with metastatic prostate cancer starting androgen-deprivation therapy (ADT) are associated with shorter time to castration-resistance and overall survival. Prostate. 2014;74:820-828.
331. Klein H, Molwitz T, Bartsch W. Steroid sulfate sulfatase in human benign prostatic hyperplasia:characterization and quantification of the enzyme in epithelium and stroma. J Steroid Biochem. 1989;33:195-200.
332. Otpuschennikov AA, Khvostova EP, Krasilnikov CE, Gulyaeva LF. Gene expression of androgen metabolising enzymes in benign prostatic hyperplasia [in English, Russian]. Klin Lab Diagn. 2013:52-54, 16-18.
333. Olive DL, Schwartz LB. Endometriosis. N Engl J Med. 1993;328:1759-1769.
334. Benedetto MT, Tabanelli S, Gurpide E. Estrone sulfate sulfatase activity is increased during in vitro decidualizadoition of stromal cells from human endometrium. J Clin Endocrinol Metab. 1990;70:342-345.
335. Falany JL, Azziz R, Falany CN. Identification and characterization of cytosolic sulfotransferases in normal human endometrium. Chem Biol Interact. 1998;109:329-339.
336. Matsuoka R, Yanaihara A, Saito H, et al. Regulation of estrogen activity inhumanendometrium:effect of IL-1β on steroid sulfatase activity in human endometrial stromal cells. Steroids. 2002;67:655-659.
337. Colette S, Defrère S, Van Kerk O, Van Langendonckt A, Dolmans MM, Donnez J. Differential expression of steroidogenic enzymes according to endometriosis type. Fertil Steril. 2013;100:1642-1649.
338. Hevir N, Ribič-Pucelj M, Lanišnik Rižner T. Disturbed balance between phase I and II metabolizing enzymes in ovarian endometriosis:a source of excessive hydroxy-estrogens and ROS? Mol Cell Endocrinol. 2013;367:74-84.
339. Purohit A, Fusi L, Brosens J, Woo LW, Potter BV, Reed MJ. Inhibition of steroid sulphatase activity in endometriotic implants by 667COUMATE:a potential new therapy. Hum Reprod. 2008;23:290-297.
340. Dassen H, Punyadeera C, Kamps R, et al. Estrogen metabolizing enzymes in endometrium and endometriosis. Hum Reprod. 2007;22:3148-3158.
341. Fusi L, Purohit A, Brosens J, Woo LW, Potter BV, Reed MJ. Inhibition of steroid sulfatase activity in endometriotic implants by STX64 (667Coumate):a potential new therapy. ScientificWorldJournal. 2008;8:1325-1327.
342. Colette S, Defrère S, Lousse JC, et al. Inhibition of steroid sulfatase decreases endometriosis in an in vivo murine model. Hum Reprod. 2011;26:1362-1370.
343. Pohl O, Bestel E, Gotteland JP. Synergistic effects of E2MATE and norethindrone acetate on steroid sulfatase inhibition:a randomized phase I proof-of-principle clinical study in women of reproductive age. Reprod Sci. 2014;21:1256-1265.
344. Shao R, Cao S, Wang X, Feng Y, Billig H. The elusive and controversial roles of estrogen and progesterone receptors in human endometriosis. Am J Transl Res. 2014;6:104-113.
345. Saegusa M, Okayasu I. Changes in expression of estrogen receptors α and β in relation to progesterone receptor and pS2 status in normal and malignant endometrium. Jpn J Cancer Res. 2000;91:510-518.
346. Smuc T, Rupreht R, Sinkovec J, Adamski J, Rizner TL. Expression analysis of estrogen-metabolizing enzymes in human endometrial cancer. Mol Cell Endocrinol. 2006; 248:114-117.
347. Berstein LM, Tchernobrovkina AE, Gamajunova VB, et al. Tumor estrogen content and clinico-morphological and endocrine features of endometrial cancer. J Cancer Res Clin Oncol. 2003;129:245-249.
348. McPherson CP, Sellers TA, Potter JD, BostickRM, Folsom AR. Reproductive factors and risk of endometrial cancer. The Iowa Women's Health Study. Am J Epidemiol. 1996; 143:1195-1202.
349. Lukanova A, Lundin E, Micheli A, et al. Circulating levels of sex steroid hormones and risk of endometrial cancer in postmenopausal women. Int J Cancer. 2004;108:425-432.
350. Thomas DB. Do hormones cause breast cancer? Cancer. 1984;53:595-604.
351. La Vecchia C, Franceschi S, Decarli A, Gallus G, Tognoni G. Risk factors for endometrial cancer at different ages. J Natl Cancer Inst. 1984;73:667-671.
352. Prefontaine M, Shih C, Pan CC, Bhavnani BR. Applicability of the product isolation and the radiometric aromatase assays for the measurement of low levels of aromatase:lack of aromatase activity in the human endometrium. J Endocrinol. 1990;127:539-551.
353. Yamamoto T, Kitawaki J, Urabe M, et al. Estrogen productivity of endometrium and endometrial cancer tissue; influence of aromatase on proliferation of endometrial cancer cells. J Steroid Biochem Mol Biol. 1993;44:463-468.
354. Abulafia O, Lee YC, Wagreich A, Economos K, Serur E, Nacharaju VL. Sulfatase activity in normal and neoplastic endometrium. Gynecol Obstet Invest. 2009;67:57-60.
355. Utsunomiya H, Ito K, Suzuki T, et al. Steroid sulfatase and estrogen sulfotransferase in human endometrial carcinoma. Clin Cancer Res. 2004;10:5850-5856.
356. Fournier MA, Poirier D. Estrogen formation in endometrial and cervix cancer cell lines:involvement of aromatase, steroid sulfatase and 17β-hydroxysteroid dehydrogenases (types 1, 5, 7 and 12). Mol Cell Endocrinol. 2009;301:142-145.
357. Foster PA, Woo LW, Potter BV, Reed MJ, Purohit A. The use of steroid sulfatase inhibitors as a novel therapeutic strategy against hormone-dependent endometrial cancer. Endocrinology. 2008;149:4035-4042.
358. Foster PA. Oestrogen and colorectal cancer:mechanisms and controversies. Int J Colorectal Dis. 2013;28:737-749.
359. Fernandez E, La Vecchia C, Balducci A, Chatenoud L, Franceschi S, Negri E. Oral contraceptives and colorectal cancer risk:a meta-analysis. Br J Cancer. 2001;84:722-727.
360. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women:principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288:321-333.
361. Zervoudakis A, Strickler HD, Park Y, et al. Reproductive history and risk of colorectal cancer in postmenopausal women. J Natl Cancer Inst. 2011;103:826-834.
362. Hendifar A, Yang D, Lenz F, et al. Gender disparities in metastatic colorectal cancer survival. Clin Cancer Res. 2009;15:6391-6397.
363. Sato R, Suzuki T, Katayose Y, et al. Steroid sulfatase and estrogen sulfotransferase in colon carcinoma:regulators of intratumoral estrogen concentrations and potent prognostic factors. Cancer Res. 2009;69:914-922.
364. English MA, Kane KF, Cruickshank N, Langman MJ, Stewart PM, Hewison M. Loss of estrogen inactivation in colonic cancer. J Clin Endocrinol Metab. 1999;84:2080-2085.
365. English MA, Stewart PM, Hewison M. Estrogen metabolism and malignancy:analysis of the expression and function of 17β-hydroxysteroid dehydrogenases in colonic cancer. Mol Cell Endocrinol. 2001;171:53-60.
366. Sato R, Suzuki T, Katayose Y, et al. Aromatase in colon carcinoma. Anticancer Res. 2012;32:3069-3075.
367. Gu S, Papadopoulou N, Gehring EM, et al. Functional membrane androgen receptors in colon tumors trigger proapoptotic responses in vitro and reduce drastically tumor incidence in vivo. Mol Cancer. 2009;8:114.
368. Alkahtani S. Testosterone induced apoptosis in colon cancer cells is regulated by PI3K/Rac1 signaling. Asian J Androl. 2013;15:831-834.
369. Tutton PJ, Barkla DH. The influence of androgens, antiandrogens, and castration on cell proliferation in the jejunal and colonic crypt epithelia, and in dimethylhydrazineinduced adenocarcinoma of rat colon. Virchows Arch B Cell Pathol Incl Mol Pathol. 1982;38:351-355.
370. Amos-Landgraf JM, Heijmans J, Wielenga MC, et al. Sex disparity in colonic adenomagenesis involves promotion by male hormones, not protection by female hormones. Proc Natl Acad Sci USA. 2014;111:16514-16519.
371. Alberg AJ, Gordon GB, Hoffman SC, Comstock GW, Helzlsouer KJ. Serum dehydroepiandrosterone and dehydroepiandrosterone sulfate and the subsequent risk of developing colon cancer. Cancer Epidemiol Biomarkers Prev. 2000;9:517-521.
372. Gillessen S, Templeton A, Marra G, Kuo YF, Valtorta E, Shahinian VB. Risk of colorectal cancer in men on longterm androgen deprivation therapy for prostate cancer. J Natl Cancer Inst. 2010;102:1760-1770.
373. Lin JH, Giovannucci E. Sex hormones and colorectal cancer:what have we learned so far? J Natl Cancer Inst. 2010; 102:1746-1747.
374. Orentreich N, Brind JL, Rizer RL, Vogelman JH. Age changes and sex differences in serum dehydroepiandrosterone sulfate concentrations throughout adulthood. J Clin Endocrinol Metab. 1984;59:551-555.
375. Valenti G, Denti L, Maggio M, et al. Effect of DHEAS on skeletal muscle over the life span:the InCHIANTI study. J Gerontol A Biol Sci Med Sci. 2004;59:466-472.
376. Kostka T, Arsac LM, Patricot MC, Berthouze SE, Lacour JR, Bonnefoy M. Leg extensor power and dehydroepiandrosterone sulfate, insulin-like growth factor-I and testosterone in healthy active elderly people. Eur J Appl Physiol. 2000;82:83-90.
377. Davis SR, ShahSM, McKenzie DP, Kulkarni J, Davison SL, Bell RJ. Dehydroepiandrosterone sulfate levels are associated with more favorable cognitive function in women. J Clin Endocrinol Metab. 2008;93:801-808.
378. Barrett-Connor E, von Mühlen D, Laughlin GA, Kripke A. Endogenous levels of dehydroepiandrosterone sulfate, but not other sex hormones, are associated with depressed mood in older women:the Rancho Bernardo study. J Am Geriatr Soc. 1999;47:685-691.
379. Shufelt C, Bretsky P, Almeida CM, et al. DHEA-S levels and cardiovascular disease mortality in postmenopausal women:results from the National Institutes of Health-National Heart, Lung, and Blood Institute (NHLBI)-sponsored Women's Ischemia Syndrome Evaluation (WISE). J Clin Endocrinol Metab. 2010;95:4985-4992.
380. BasarMM, Aydin G, MertHC, et al. Relationship between serum sex steroids and Aging Male Symptoms score and International Index of Erectile Function. Urology. 2005; 66:597-601.
381. Davis SR, Davison SL, Donath S, Bell RJ. Circulating androgen levels and self-reported sexual function in women. JAMA. 2005;294:91-96.
382. Luu-The V, Labrie F. The intracrine sex steroid biosynthesis pathways. Prog Brain Res. 2010;181:177-192.
383. Legrain S, Massien C, Lahlou N, et al. Dehydroepiandrosterone replacement administration:pharmacokinetic and pharmacodynamic studies in healthy elderly subjects. J Clin Endocrinol Metab. 2000;85:3208-3217.
384. Aspinall SR, Stamp S, Davison A, Shenton BK, Lennard TW. The proliferative effects of 5-androstene-3 β, 17 β-diol and 5 α-dihydrotestosterone on cell cycle analysis and cell proliferation in MCF7, T47D and MDAMB231 breast cancer cell lines. J Steroid Biochem Mol Biol. 2004; 88:37-51.
385. Davison SL, Davis SR. Androgens in women. J Steroid Biochem Mol Biol. 2003;85:363-366.
386. Rosenfeld RS, Rosenberg BJ, Fukushima DK, Hellman L. 24-Hour secretory pattern of dehydroisoandrosterone and dehydroisoandrosterone sulfate. J Clin Endocrinol Metab. 1975;40:850-855.
387. Kroboth PD, Salek FS, Pittenger AL, Fabian TJ, Frye RF. DHEA and DHEA-S:a review. J Clin Pharmacol. 1999; 39:327-348.
388. Bonney RC, Scanlon MJ, Reed MJ, Jones DL, Beranek PA, James VH. Adrenal androgen concentrations in breast tumours and in normal breast tissue. The relationship to oestradiol metabolism. J Steroid Biochem. 1984;20:501-504.
389. Geisler J, Sasano H, Chen S, Purohit A. Steroid sulfatase inhibitors:promising new tools for breast cancer therapy? J Steroid Biochem Mol Biol. 2011;125:39-45.
390. Maltais R, Poirier D. Steroid sulfatase inhibitors:a review covering the promising 2000-2010 decade. Steroids. 2011;76:929-948.
391. Williams SJ. Sulfatase inhibitors:a patent review. Expert Opin Ther Pat. 2013;23:79-98.
392. Purohit A, Woo LW, Singh A, Winterborn CJ, Potter BV, Reed MJ. In vivo activity of 4-methylcoumarin-7-O-sulfamate, a nonsteroidal, nonestrogenic steroid sulfatase inhibitor. Cancer Res. 1996;56:4950-4955.
393. Foster PA, Newman SP, Chander SK, et al. In vivo efficacy of STX213, a second-generation steroid sulfatase inhibitor, for hormone-dependent breast cancer therapy. Clin Cancer Res. 2006;12:5543-5549.
394. Foster PA, Chander SK, Parsons MF, et al. Efficacy of three potent steroid sulfatase inhibitors:pre-clinical investigations for their use in the treatment of hormone-dependent breast cancer. Breast Cancer Res Treat. 2008;111:129-138.
395. LawrenceWooLW, Leblond B, Purohit A, Potter BV. Synthesis and evaluation of analogues of estrone-3-O-sulfamate as potent steroid sulfatase inhibitors. Bioorg Med Chem. 2012;20:2506-2519.
396. Phan CM, Liu Y, Kim BM, Mostafa Y, Taylor SD. Inhibition of steroid sulfatase with 4-substituted estrone and estradiol derivatives. Bioorg Med Chem. 2011;19:5999-6005.
397. Mostafa YA, Taylor SD. 17β-Arylsulfonamides of 17β-aminoestra-1, 3, 5(10)-trien-3-ol as highly potent inhibitors of steroid sulfatase. Bioorg Med Chem. 2012;20:1535-1544.
398. Rasmussen LM, Zaveri NT, Stenvang J, Peters RH, Lykkesfeldt AE. A novel dual-target steroid sulfatase inhibitor and antiestrogen:SR16157, a promising agent for the therapy of breast cancer. Breast Cancer Res Treat. 2007;106:191-203.
399. Foster PA, Chander SK, Newman SP, et al. A new therapeutic strategy against hormone-dependent breast cancer:the preclinical development of a dual aromatase and sulfatase inhibitor. Clin Cancer Res. 2008;14:6469-6477.
400. Verdugo DE, Cancilla MT, Ge X, et al. Discovery of estrogen sulfotransferase inhibitors from a purine library screen. J Med Chem. 2001;44:2683-2686.
401. Armstrong JI, Portley AR, Chang YT, et al. Discovery of carbohydrate sulfotransferase inhibitors from a kinasedirected library We thank Sharon Long and Dave Keating for providing both the NodH sulfotransferase and APS kinase during our preliminary experiments and Jack Kirsch for numerous helpful conversations. J.I.A. and K.G.B were supported by NIH Molecular Biophysics Training Grant (No. T32GM0895). This research was funded by grants to C.R.B. from the Pew Scholars Program, the W. M. Keck Foundation and the American Cancer Society (Grant No. RPG9700501BE). Angew Chem Int Ed Engl. 2000;39:1303-1306.
402. Chapman E, Ding S, Schultz PG, Wong CH. A potent and highly selective sulfotransferase inhibitor. JAmChem Soc. 2002;124:14524-14525.
403. Armstrong JI, Verdugo DE, Bertozzi CR. Synthesis of a bisubstrate analogue targeting estrogen sulfotransferase. J Org Chem. 2003;68:170-173.
404. Armstrong JI, Ge X, Verdugo DE, Winans KA, Leary JA, Bertozzi CR. A library approach to the generation of bisubstrate analogue sulfotransferase inhibitors. Org Lett. 2001;3:2657-2660.
405. Rath VL, Verdugo D, Hemmerich S. Sulfotransferase structural biology and inhibitor discovery. Drug Discov Today. 2004;9:1003-1011.
406. Schuksz M, Fuster MM, Brown JR, et al. Surfen, a small molecule antagonist of heparan sulfate. Proc Natl Acad Sci USA. 2008;105:13075-13080.
407. Mencio C, Garud DR, Kuberan B, KoketsuM. Synthesis of selective inhibitors of heparan sulfate and chondroitin sulfate proteoglycan biosynthesis. Methods Mol Biol. 2015; 1229:69-78.
408. Fokidis HB, Adomat HH, Kharmate G, Hosseini-Beheshti E, Guns ES, Soma KK. Regulation of local steroidogenesis in the brain and in prostate cancer:lessons learned from interdisciplinary collaboration. Front Neuroendocrinol. 2015;36:108-129.
409. Cobice DF, Mackay CL, Goodwin RJ, et al. Mass spectrometry imaging for dissecting steroid intracrinology within target tissues. Anal Chem. 2013;85:11576-11584.
410. Harteneck C. Pregnenolone sulfate:from steroid metabolite to TRP channel ligand. Molecules. 2013;18:12012-12028.
411. Teng Y, Litchfield LM, Ivanova MM, Prough RA, Clark BJ, Klinge CM. Dehydroepiandrosterone-induces miR-21 transcription in HepG2 cells through estrogen receptor β and androgen receptor. Mol Cell Endocrinol. 2014;392:23-36.
412. Shihan M, Kirch U, Scheiner-Bobis G. Dehydroepiandrosterone sulfate mediates activation of transcription factors CREB and ATF-1 via aGα11-coupled receptor in the spermatogenic cell line GC-2. Biochim Biophys Acta. 2013; 1833:3064-3075.
413. Radford DJ, WangK, McNelis JC, et al. Dehydroepiandrosterone sulfate directly activates protein kinase C-β to increase human neutrophil superoxide generation. Mol Endocrinol. 2010;24:813-821.
414. Ekuase EJ, Liu Y, Lehmler HJ, RobertsonLW, DuffelMW. Structure-activity relationships for hydroxylated polychlorinated biphenyls as inhibitors of the sulfation of dehydroepiandrosterone catalyzed by human hydroxysteroid sulfotransferase SULT2A1. Chem Res Toxicol. 2011;24:1720-1728.
415. Chang HJ, Shi R, Rehse P, Lin SX. Identifying androsterone (ADT) as a cognate substrate for human dehydroepiandrosterone sulfotransferase (DHEA-ST) important for steroid homeostasis:structure of the enzyme-ADT complex. J Biol Chem. 2004;279:2689-2696.
416. Falany CN, Vazquez ME, Kalb JM. Purification and characterization of human liver dehydroepiandrosterone sulphotransferase. Biochem J. 1989;260:641-646.
417. Chang HJ, Zhou M, Lin SX. Human dehydroepiandrosterone sulfotransferase:purification and characterization of a recombinant protein. J Steroid Biochem Mol Biol. 2001;77:159-165.
418. Nishiyama T, Ogura K, Nakano H, et al. Sulfation of environmental estrogens by cytosolic human sulfotransferases. Drug Metab Pharmacokinet. 2002;17:221-228.
419. Hempel N, Barnett AC, Bolton-Grob RM, Liyou NE, Mc-Manus ME. Site-directed mutagenesis of the substratebinding cleft of human estrogen sulfotransferase. Biochem Biophys Res Commun. 2000;276:224-230.
420. Sun M, Leyh TS. The human estrogen sulfotransferase:a half-site reactive enzyme. Biochemistry. 2010;49:4779-4785.
421. Gamage NU, Tsvetanov S, Duggleby RG, McManus ME, Martin JL. The structure of human SULT1A1 crystallized with estradiol. An insight into active site plasticity and substrate inhibition with multi-ring substrates. J Biol Chem. 2005;280:41482-41486.
422. Loubière LS, Vasilopoulou E, Bulmer JN, et al. Expression of thyroid hormone transporters in the human placenta and changes associated with intrauterine growth restriction. Placenta. 2010;31:295-304.
423. Wang H, Yan Z, Dong M, Zhu X, Wang H, Wang Z. Alteration in placental expression of bile acids transporters OATP1A2, OATP1B1, OATP1B3 in intrahepatic cholestasis of pregnancy. Arch Gynecol Obstet. 2012;285:1535-1540.
424. Meier PJ, Eckhardt U, Schroeder A, Hagenbuch B, Stieger B. Substrate specificity of sinusoidal bile acid and organic anion uptake systems in rat and human liver. Hepatology. 1997;26:1667-1677.
425. Lee W, Glaeser H, Smith LH, et al. Polymorphisms in human organic anion-transporting polypeptide 1A2 (OATP1A2):implications for altered drug disposition and central nervous system drug entry. J Biol Chem. 2005;280:9610-9617.
426. Svoboda M, Wlcek K, Taferner B, et al. Expression oforganic anion-transporting polypeptides 1B1 and 1B3 in ovarian cancer cells:relevance for paclitaxel transport. Biomed Pharmacother. 2011;65:417-426.
427. Sun YN, Liu YJ, Zhang L, et al. Expression of organic anion transporting polypeptide 1c1 and monocarboxylate transporter 8 in the rat placental barrier and the compensatory response to thyroid dysfunction. PLoS One. 2014; 9:e96047.
428. van der Deure WM, Appelhof BC, Peeters RP, et al. Polymorphisms in the brain-specific thyroid hormone transporter OATP1C1 are associated with fatigue and depression in hypothyroid patients. Clin Endocrinol (Oxf). 2008; 69:804-811.
429. Wlcek K, Svoboda M, Riha J, et al. The analysis of organic anion transporting polypeptide (OATP) mRNA and protein patterns in primary and metastatic liver cancer. Cancer Biol Ther. 2011;11:801-811.
430. St-Pierre MV, Hagenbuch B, Ugele B, Meier PJ, Stallmach T. Characterization of an organic anion-transporting polypeptide (OATP-B) in human placenta. J Clin Endocrinol Metab. 2002;87:1856-1863.